CORD-19:5e8abc62533a447422d5ead64d4ae4991cc99052 / 63088-63402 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/5e8abc62533a447422d5ead64d4ae4991cc99052","sourcedb":"CORD-19","sourceid":"5e8abc62533a447422d5ead64d4ae4991cc99052","text":"Therefore, these findings provide clues for further XKB-based drug development and clinical use, including structural modification or nanotechnology-based formulations to minimize or avoid its potential side effects and prolong its elimination half-life to achieve therapeutic concentrations at the site of action.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T486","span":{"begin":0,"end":314},"obj":"Sentence"},{"id":"T11493","span":{"begin":0,"end":314},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"TextSentencer_T486","pred":"source","obj":"CORD-19-Sentences"},{"subj":"T11493","pred":"source","obj":"CORD-19-Sentences"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#ecdc93","default":true}]}]}}